Modified version which contains information viewed on PTO/SB/08A (08-03) which has been proved for use through 07/31/2008. OMB 0651-0031 This is a substitute for form 1449/PTO

#### INFORMATION DISCLOSURE STATEMENT BY APPEICANT

(use as many sheets as necessary)

Sheet 1 of 4

AUG 1 6 2004

Application Number	10/657,045
Filing Date	09/04/03
First Named Inventor	Tedeschi et al.
Group Art Unit	1615
Examiner Name	Fubara, Blessing M.
Attorney Docket Number	P297CON2 (51288-00061US)

		<u> </u>				
		Councillo.	PATENT DOCUMENTS			
EXAMINER INITIALS	DOCUMENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ME	4,373,009	02/08/83	Winn	428	424.2	II AFFROFRIATE
j	4,585,666	04/29/86	Lambert	427	2	<del></del>
$\wedge$	4,625,012	11/25/86	Rizk et al.	528	28	<del></del>
	4,894,231	01/16/90	Moreau et al.	424	426	
	5,032,666	07/16/91	Hu et al.	528	70	/-
	5,040,544	08/20/91	Lessar et al.	607	122	
	5,134,192	07/28/92	Feijen et al.	525	54.1	
	5,171,217	12/15/91	March et al.	604	507	<del></del>
	5,380,299	01/10/95	Fearnot et al.	604	265	
	5,383,928	01/24/95	Scott et al.	623	1.12	
	5,447,724	09/05/95	Heimus et al.	424	426	
	5,464,650	11/07/95	Berg et al.	427	2.3	
	5,470,307	11/28/95	Lindall	604	20	
	5,512,055	04/30/96	Domb et al.	604	265	
	5,525,348	06/11/96	Whitbourne et al.	424	423	
	5,554,182	09/10/96	Dinh et al.	600	36	
	5,562,922	10/08/96	Lambert	424	486	<del></del>
	5,571,089	11/05/96	Crocker	604	103.01	
	5,591,227	01/07/97	Dinh et al.	623	1.22	
	5,605,696	02/25/97	Eury et al.	424	423	
	5,609,629	03/11/97	Fearnot et al.	623	1.42	
	5,612,052	03/18/97	Shalaby	424	426	<del></del>
	5,624,411	04/29/97	Tuch	604	265	
	5,637,113	06/10/97	Tartaglia et al.	623	1.42	
	5,645,931	07/08/97	Fan et al.	428	334	
	5,660,873	08/26/97	Nikolaychik et al.	427	2.24	
	5,662,960	09/02/97	Hostettler et al.	427	2.3	
	5,674,192	10/07/97	Sahatjian et al.	604	28	<del>-  </del>
	5,683,451	11/04/97	Lenker et al.	623	1.11	
	5,698,738	12/16/97	Garfield et al.	564	112	
	5,700,286	12/23/97	Tartaglia et al.	623	1.15	
	5,702,754	12/30/97	Zhong	427	2.12	/
	5,705,583	01/06/98	Bowers et al.	526	277	1
	5,756,145	05/26/98	Darouiche	427	2.24	/
the l	5,756,553	05/26/98	Iguchi et al.	514	772.3	<del>/</del>

EXAMINER
SIGNATURE

DATE
CONSIDERED

CONSIDERED

LU-3 I-O LU

This collection of information is required by 37 CFR 1 97 land 1.08. The information is required to obtain or retain a benefit by the public which is to the (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to late 2 focus to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burder, should be sent to the Chief Intormation Officer. U.S. Patient and Trandemark Office, P.O. Box 1450, Alexandria, V.A. 2231-3-1450. If you need assistance in completing the form, cell 1-500-279-9199 (1-300-789-9199) and select option 2.

EXAMINER: Initial II reterence considered, whether or not classion is in conformance with the through classion in on formormance and not completely the form, cell 1-500-779-9199 (1-300-789-9199) and select option 2.

Applicant's unique cluster designation number (optional). 2 See Kinds Codes of USPTO Patient Documents at www.uspto.gov or MPCP 901.04. 3 Enter Office that issued the document, by the two-letter code (WPC) Standard ST.1.3 if possible, 6 Applicant is to place a check mark here if English language Translation is estached.

Modified version which contains information viewed on PTO/SB/08A (08-03) which has been proved for use through 07/31/2006, OMB 0651-0031 This is a substitute for form 1449/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

<del>~~`~~~~~~~</del>	
Application Number	10/657,045
Filing Date	09/04/03
First Named Inventor	Tedeschi et al.
Group Art Unit	1615
Examiner Name	Fubara, Blessing M.
Attorney Docket Number	P297CON2 (51288-00061US)

( Brc.)	5,762,944	06/09/98	Inoue et al.	404	1 400	·
1	5,770,229	06/23/98	Tanihara et al.	424	400	
	5,776,611	07/07/98		424	488	
-	5,792,106		Elton et al.	428	423.1	
<del></del>		08/11/98	Mische	604	103.01	
<del></del>	5,797,887	08/25/98	Rosen et al.	604	265	
	5,824,049	10/20/98	Ragheb et al.	623	1.44	
<del> +</del>	5,824,054	10/20/98	Khosravi et al.	623	1.44	
<del> </del>	5,843,120	12/01/98	Israel et al.	523	1.15	
	5,843,166	12/01/98	Lentz et al.	623	1.13	
<del>          </del>	5,843,172	12/01/98	Yan	623	1.42	_
	5,849,368	12/15/98	Hostettler et al.	427	536	
	5,853,745	12/29/98	Darouiche	424	423	
	5,869,127	02/09/99	Zhong	427	2.12	
	5,873,904	02/23/99	Ragheb et al.	623	1.13	
	5,891,108	04/06/99	Leone et al.	604	264	
	5,900,246	05/04/99	Lambert	424	429	
	5,919,570	07/06/99	Hostettler et al.	428	424.8	
	5,972,027	10/26/99	Johnson	623	1.42	<del></del>
	5,997,517	12/07/99	Whitebourne	604	265	
	6,024,763	02/15/00	Lenker et al.	606	191	
	6,048,360	04/11/00	Khosravi et al.	623	1.11	
	6,090,901	07/18/00	Bowers et al.	526	277	
	6,096,070	08/01/00	Ragheb et al.	623	1.39	
	6,153,252	11/28/00	Hossainy et al.	427	2.3	
	6,156,345	12/05/00	Chudzik et al.	424	485	
	6,197,051	03/06/01	Zhong	623	1.46	
	6,214,901	04/10/01	Chudzik et al.	523	113	
	6,254,632	07/03/01	Wu et al.	623	1.15	
	6,258,121	07/10/01	Yang et al.	623	1.46	<del></del>
	6,287,285	09/11/01	Michal et al.	604	264	<del></del>
	6,299,604	10/09/01	Ragheb et al.	604	265	<del></del>
	6,306,176	10/23/01	Whitbourne	623	23.59	
	6,344,035	02/05/02	Chudzik et al.	604	265	
	6,355,060	03/12/02	Lenker et al.	623	1.34	
	6,379,382	04/30/02	Yang	623	1.42	
	6,451,050	09/17/02	Rudakov et al.	623	1.15	<del></del>
BA	6,451,373	09/17/02	Hossainy et al.	427		
C-18	0,,575	07/1/102	11035ailly et al.	42/	2.25	

EXAMINER	21	$\sim$ 1	DATE	
SIGNATURE	10 15 15 1 NG	tuhan.	DATE	10-21-21
SIGNATURE	147.0	1 Volume	CONSIDERED	103104

Modified version which contains information viewed on PTO/SB/08A (08-03) which has been proved for use through 07/31/2006. OMB 0651-0031

This is a substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Application Number	10/657,045
Filing Date	09/04/03
First Named Inventor	Tedeschi et al.
Group Art Unit	1615
Examiner Name	Fubara, Blessing M.
Attorney Docket Number	P297CON2 (51288-00061US)

SF.	6,458,152	10/01/02	Khosravi et al.	623	1.13	
	6,488,701	12/03/02	Nolting et al.	623	1.13	
	6,506,437	01/14/03	Harish et al.	427	2.25	
PFI	6,547,814	04/15/03	Edwin et al.	623	1.13	

		FOREIGN I	PATENT DOCUMENTS		<del></del>		
EXAMINER INITIALS	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANS	ATION
bi-	357401B1	3/90	EP.		10000	X	140
BF	352295 B1	6/93	EP			$\frac{x}{x}$	
K	397784 B1	10/93	EP			$\frac{x}{x}$	

	OTHER DOCUMENTS					
EXAMINER INITIALS	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
BC	Adams et al., "Inhibition of Nitric Oxide Synthase Disrupts Inhibitory Gating of Auditory Responses					
Ĺ	Berkenbosch et al., "Management of Postoperative Chylothorax with Nitric Oxide: A Case Report," Critical Care Medicine, 27:1022-4 (May 1999)					
	Carrier et al., "Nitric Oxide Inhalation in the Treatment of Primary Graft Failure Following Heart Transplantation," The Journal of Heart and Lung Transplantation, 18:664-7 (July 1999)					
	Cooper et al., "Transient Loss of Resistance to Pulmonary Tuberculosis in p47PHOX-/-Mice," Infection and Immunity, 68:1231-4 (March 2000)					
	El-Haddad et al., "Nitric Oxide Modulates Spontaneous Swallowing Behaviour in Near-Term Ovine Fetus," American Journal of Physiology, 277:R981-6 (October 1999)					
	Freedman, et al., "Acute Effect of Nitric Oxide on Raynaud's Phenomenon in Scleroderma," The Lancet, 354:739 (August 1999)					
	Goodwin et al., "Favorable Response of Eisenmenger Syndrome to Inhaled Nitric Oxide During Pregnancy," American Journal of Obstetrics and Gynecology, 180:64-7 (January 1999)					
	Gradini et al., "Nitric Oxide Synthases in Normal and Benign Hyperplastic Human Prostate: Immunohistochemistry and Molecular Biology," Journal of Pathology, 189:224-9 (October 1999)					
	Holopainen et al., "Nitric Oxide Inhalation Inhibits Pulmonary Apoptosis but not Inflammatory Injury in Porcine Meconium Aspiration," Acta Paediatrica, 88:1147-55 (October 1999)					
bf	Ishihara et al., "Inhaled Nitric Oxide Prevents Left Ventricular Impairment During Endotoxemia,"  Journal of Applied Physiology, 85:2018-24 (December 1998)					

EXAMINER	2) (2)	$\sim$ 7	DATE		<del></del>
SIGNATURE	D16 8129	Tusara	CONSIDERED	10-31-00	
This collection of informs	tion is required by 37 CFR 1/87 ar	d 1.98. The information is required to obta	ain or retain a benefit by the public which is to file (and by the	USPTO to process) an application Confidentiality is no	Manual by 35 (19 C 172

and 37 CFR 1.14. This collection is estimated to tail® 2 hours to complete, including gathering, preparing, and submitting the completed application. The user of the user of

Modified version which contains information viewed on PTO/SB/08A (08-03) which has been proved for use through 07/31/2006. OMB 0651-0031 This is a substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Application Number	10/657,045
Filing Date	09/04/03
First Named Inventor	Tedeschi et al.
Group Art Unit	1615
Examiner Name	Fubara, Blessing M.
Attorney Docket Number	P297CON2 (51288-00061US)

BF	Jacobs et al., "Aerosolized Soluble Nitric Oxide Donor Improves Oxygenation and Pulmonary Hypertension in Acute Lung Injury," American Journal of Respiratory and Critical Care Medicine, 158:1536-42 (November 1998)
	Kiris et al., "Reversal of Cerebral Vasospasm by the Nitric Oxide Donor SNAP in an Experimental Model of Subarachnoid Haemorrhage," Acta Neurochirurgica, 141:1323-9 (1999)
	Lambermont et al., "Effects of Inhaled Nitric Oxide on Pulmonary Hemodynamics in a Porcine Model of Endotoxin Shock," Critical Care Medicine, 27:1953-7 (September 1999)
	Lewis et al., "Nitric Acid Limits the Eicosanoid-Dependant Bronchoconstriction and Hypotension Induced By Endothelin-1 in the Guinea Pig," British Journal of Pharmacology, 126:93-102 (January 1999)
	Payen, et al., "Inhaled Nitric Oxide, Almitrine Infusion, or Their Coadministration as a Treatment of Severe Hypoxemic Focal Lung Lesions," Anesthesiology, 89:1157-65 (November 1998)
	Samama et al., "Inhibition of Nitric Oxide Synthase Impairs Early Olfactory Associative Learning in Newborn Rats," Neurobiology of Learning and Memory, 71:219-31 (March 1999)
BF	Sullivan et al., "Nitric Oxide Successfully used to treat Acute Chest Syndrome of Sickle Cell Disease in a Young Adolescent," Critical Care Medicine, 27:2563-8 (November 1999)

EXAMINER	i.	1		DATE	
SIGNATURE	υ	1035114	Tusara	CONSIDERED	10-3i-0

This collection of information is required by 37 CFR 1.91 agd 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Contributinitity is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 moles to complete, including pathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestores for reducing this burden, should be sent to the Chief information Officer, U.S. Patient and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1456, DO NOT SEND FEEB OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for patients, P.O. Box 1450, Alexandria, VA 22313-1456, DO NOT SEND FEEB OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for patients, P.O. Box 1450, Alexandria, VA 22313-1456, DO NOT SEND FEEB OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for patients, P.O. Box 1450, Alexandria, VA 22313-1456, DO NOT SEND FEEB OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for patients, P.O. Box 1450, Alexandria, VA 22313-1456, DO NOT SEND FEEB OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for patients, P.O. Box 1450, Alexandria, VA 22313-1456, DO NOT SEND FEEB OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for patients of the complete and trade of the complete and trade to the complete and trad

PTO/SB/08A (08-03) Approved for use through 07/31/2006 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

95, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known

**Application Number** 

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Reduction Act of

1

Under the Paperwood Reduction A Substitute for form 1

Sheet

(use as many sheets as necessary)

of

3

10/657,045 Filing Date 09/04/2003 First Named Inventor Fitzhugh et al. Group Art Unit 1616 **Examiner Name Attorney Docket Number** 

14364-0108

			U.S. PATENT DOCUMEN	ITS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials	No.1	Number-Kind Code <sup>2 (K known)</sup>	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
&F	1	US - 4,954,526	09-04-1990	Keefer	rigures Appear
+	2	US - 5,039,705	08-13-1991	Keefer et al.	
	3	US - 5,155,137	10-13-1992	Keefer et al.	<del>                                     </del>
-	4	US - 5,171,217	12-15-1992	March et al.	<del> </del>
	_ 5	US - 5,212,204	05-18-1993	Keefer et al.	<del>                                     </del>
	6	US - 5,229,172	07-20-1993	Cahalan et al.	
-	7	US - 5,250,550	10-05-1993	Keefer et al.	<del>                                     </del>
	8	US - 5,268,465	12-07-1993	Bredt et al.	<del>                                     </del>
	9	US - 5,366,997	11-22-1994	Keefer et al.	<del>                                     </del>
_	10	US - 5,380,758	01-10-1995	Stamler et al.	<del> </del>
	11	US - 5,405,919	04-11-1995	Keefer et al.	<del>                                     </del>
	12	US - 5,428,070	06-27-1995	Cooke et al.	<del> </del>
	13	US - 5,468,630	11-21-1995	Billiar et al.	<del>                                     </del>
	14	US - 5,482,925	01-09-1996	Hutsell	<del>                                     </del>
	15	US - 5,519,020	05-21-1996	Smith et al.	<del>                                     </del>
	16	US - 5,525,357	06-11-1996	Keefer et al.	<del></del>
	17	US - 5,574,068	11-12-1996	Stamler et al.	<del>       </del>
	18	US - 5,583,101	12-10-1996	Stamler et al.	<del>       </del>
_   _	19	US - 5,632,981	05-27-1997	Saavedra et al.	<del>                                     </del>
	20	US - 5,650,447	07-22-1997	Keefer et al.	<del>  </del>
	21	US - 5,658,565	08-19-1997	Billar et al.	<del></del>
	22	US - 5,676,963	10-14-1997	Keefer et al.	<del></del>
	23	US - 5,683,668	11-04-1997	Hrabie et al.	<del></del>
	24	US - 5,691,423	11-25-1997	Smith et al.	
	25	US - 5,700,830	12-23-1997	Korthuis et al.	<del>/</del>
	26	US - 5,714,511	02-03-1998	Saavedra et al.	
	27	US - 5,718,892	02-17-1998	Keefer et al.	
	28	US - 5,721,365	02-24-1998	Keefer et al.	
	29	US - 5,770,645	06-23-1998	Stamler et al.	
		US - 5,789,447	08-04-1998	Wink, Jr. et al.	
	31	US - 5,814,656	09-29-1998	Saavedra et al.	
	32	US - 5,814,667	09-29-1998	Mitchell et al.	
		US - 5,837,736	11-17-1998	Mitchell et al.	/
16C-		US - 5,837,313	11-17-1998		
			11-11-1990	Ding et al.	

Examiner Date Signature 10-31-01 Considered

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation it not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.4. Enter Office that issued the fundaments, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. Sind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 15 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to processO and application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is stirmated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application of to the USPTO. Three will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS,

PTO/SB/08A (08-03)

Approved for use through 07/31/2006.OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO

			. •						Co	omplete i	f Kno	own		
				-			Application	on Nu	mber	1	10/65	7,045		
INFORMATION DISCLOSURE						Filing Date				09/04/2003				
STATEMENT BY APPLICANT						First Nam	ned In	ventor	-	itzhu	igh et al.			
								t Unit			616	3		
		(use as	many sheet	ts as neces	sary)		Examine							
Shee	et		2	of		3	Attorney			r 1	4364	1-0108		
					Ū.	S PATENT I				<u></u>				
Fuerning	Document Number			<u> </u>	U.S. PATENT DOCUMENTS  Publication Date Name of Patentee or				entee or	Pages, Columns, Lines, W			VA/Ib	
Examiner Initials	Cite No.1	Nun	nber-Kind Co	vdo <sup>2</sup> (if known)		MM-DD-YYYY		Applicant of Cited			Relevant Passages o		-⊪nes, s or R	wnere elevant
GF	35	US-	5,840,759	, de	<del> </del>	11 24 1000		1	Docume			Figures Ap	pear	
7	36		5,877,216		1	11-24-1998 03-02-1999			itchell et ace et al					
	37	US -	5,891,459			04-06-			ooke et a					
· .	38		5,910,316			06-08-			efer et a				-	
	39		5, <b>94</b> 5,452			08-31-			oke et a					
1.	40		5,958,427			09-28-	1999		Izman el					
	41 42		5,962,520		<b>↓</b>	10-05-			nith et al.			<del>-/</del>		
The	43		5,994,444 6,024,918		-	11-30-		Tre	escony e	t al.				
L	40	103-1	0,024,918			02-15-	2000	He	ndriks et	al.	$\angle$			
					FORE									
	T —	Γ	Foreign Pate	ent Documen	FORE	IGN PATENT	DOCUME	NTS						
_	ł					J						Pages, Colum		
Examiner Initials	Cite No.1		Numi		Kind	Kind Name of Patentee or Applicant of Cited Document		ant of Date of Publication		Lines, Where Relevant Passages			T <sup>6</sup>	
	140.				Code				of Cited Document		its or Relevant Figures			<u> </u>
155		WO 00/02501			William Harvey Research LTD.		D.	01-20-20		+-	Appear		ł	
he	L	wo	0030658		A1	Smith et al. 06-02-2000		00	+			ł		
			OTHE	R PRIOR	ART -	NON PATEN	T LITERAT	URE	DOCUM	ENTS				
Examiner	Cite	-	III ICIUUH II	wille of the F	אט זראמזווו	CADITAL LETTE	DON MALE ELL				title o	f the	$T^{-}$	
Initials	Examiner Initials No. item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  Keefer, et al; "NONOates" (1-Substituted Diazen-1-lum-1,2-diolates) as Nitric Oxide Dosage Forms." Methods in Examples 1,000 and 1							T <sup>2</sup>						
- PoC		Nitric O	, et al; "NON( )xide Dosage	Oates" (1-St	hatutitadi	Dig zon_1_i.um_1 :	an (antalalb C	Allenda	Oxide Dono	rs: "Conve	nient		+-	
54		Saavedra, et al.: Conversion of Polyspechadot to Nitro October 281-293								/				
		Anticoagulant Activity of Diazeniumdiolated Heparin." Bioorganic & Medicinal Chemistry Letters 10 (2000)								· /				
		Hrable, et al; "New Nitric Oxide-Releasing Zwitterions Derived from Polyamines ", 1 Ox. 21												
		Chandy, et al; "Use of Plasma Glow for Surface-Engineering Biomolecules to Enhance Bloodcompatibility of Dacron and PTFE Vascular Prosthesis." Biomaterials 21 (2000): 699-712												
		Drago, Russell S.; "Reactions of Nitrogen(III) Ovide" No. 36 Advances in Charital St.												
		Bauer et al.; Evaluation of Linear Polyethyleneimine/nitric Oxide Adduct on Wound Repair: Therapy versus Toxicity; Wound Repair & Regeneration, November/December 1998, pp. 569/577												
1 7	-	Hanson et al.; Nitric Oxide Donors: A Continuing Opportunity in Drug Design: Advances in Physics												
<del></del>	···												17	
- AC		1999, pr	0.367/425		e excius	ion Chromatogra	phy; Column	Handb	ook for Siz	e Exclusio	n Chr	omotography;	11	$\neg \neg$
<del></del>													<u> </u>	
Examiner		Ri	256,0		1			Date	•	Γ				
Signature		101	c 211 1~	, <u> </u>	) . la =	res.		1 ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	-			_		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.usoto.gov">www.usoto.gov</a> or MPEP 901.4. Tenter Office that issued the source of the reign of the Emperor must precede the serial number of the patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. Sind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to processO and application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is stitumeted to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application! USPTO. Time will vary depending upon the individual cass. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to

substitute for form	1449A/PTO	a porcons a	re required to re-	spond to a collection of information unles	es it contains a valid OMB control number ete if Known	
		-		Application Number	10/657,045	
		N DISCLOSUF		Filing Date	09/04/2003	
\$T	ATEMENT I	BY APPLICAN	IT	First Named Inventor	Fitzhugh et al.	
				Group Art Unit	1616	
	use as many she	ets as necessary)		Examiner Name		
Sheet	3	of	3	Attorney Docket Number	14364-0108	

65	Downey et al.; Growth Mechanism of Poly(divinylbenzene) Microspheres in Precipitation Polymerization; American Chemical Society, Easton, US, Vol. 32, No. 4, 4 May 1999; pgs 2838-2844	
	Journal of Biomedical Materials Research: Wiley New York NY Vol 97 https://doi.org/10.1007/10.	
	Vol. 40, No. 2, 1999, pos 799-800	
	Kaul et al.; Polymeric/Based Perivascular Delivery of a Nitric Oxide Donor Inhibits Intimal Thicening After Balloon Denudation Arterial Injury: Role of Nuclear Factor/kappaB; Journal of the American College of Cardiology, Vol. 35, No. 2, 2000:493/501	
	Mowery et al.; Preparation and Characterization of Hydrophobic Polymeric Films That Are Thromboresistant Via Nitric  Oxide Release; Biomaterials 21 (2000) 9/21	
boe	Smith et al.; Nitric Oxide/Releasing Polymers Containing the [N(O)NO] Group; J.Med.Chem. 1996, 39, 1148/1156	

Examiner	7 1			
Signature	15 d 26	h ./	Date	
Signature	10/01/109	1 49/10	Considered	100 21
AEVALUEED, 1-10-4 M	<del></del>		Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.4. \*Enter Office that issued the kind of document by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to processO and application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is stitmated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application! Or to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, Patent and Trademark Office, US Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.